Skip to content
DraconiticResearch
Search Sources API
203,234 studies31 sourcesUpdated 23 min ago
Peer-reviewedCC BY 4.0Frontiers in Oncology

Potassium inward rectifier channel subfamily J member 11 mRNA expression in glioma and its significance in predicting prognosis and chemotherapy sensitivity

  • Kaijia Zhou1
  • Bing Zhou2
  • Qiang Gu1
  • Tingming Lu1
  • Qingxian Ke1
  • Xiaoyin Liu1
  • Jin Xu1
  • Xinyan Zhang2
  1. 1Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fujian Branch of Fudan University Shanghai Cancer Cente
  2. 2Basic Medical College of Fujian Medical University
Read full textPDFDOICite

Abstract

Background: This study aimed to characterize the expression profile of potassium inward rectifier channel subfamily J member 11 (KCNJ11) across diverse pathological subtypes of glioma based on clinical samples from our single-center cohort. We further explored the predictive value of KCNJ11 mRNA expression for overall prognosis and temozolomide chemosensitivity in glioma patients, and validated its clinical predictive efficiency.

Methods: A total of 516 glioma patients treated at the Neuro-Oncology Surgery Department of Fujian Cancer Hospital between 2006.01and 2025.01 were enrolled as the discovery cohort. Complete clinical information including gender, age, pathological subtype, WHO histological grade, IDH mutation status, 1p/19q co-deletion status, survival outcome and KCNJ11 mRNA expression levels were retrospectively collected. Univariate and multivariate Cox proportional hazards regression models were constructed to screen independent prognostic biomarkers for glioma. Three independent public glioma datasets were applied for external validation: 603 glioma cases from The Cancer Genome Atlas (TCGA), 284 cases from the Repository for Molecular Brain Neoplasia Data (REMBRANDT), and 264 cases from GSE16011 dataset in NCBI Gene Expression Omnibus (GEO). Correlations between KCNJ11 mRNA expression, clinical molecular features and overall survival (OS) were verified across all validation cohorts.

Results: In our single-center discovery cohort of 516 glioma patients hospitalized from 2006 to 2025, KCNJ11 mRNA expression was significantly correlated with pathological subtype, WHO grade, IDH mutation, 1p/19q co-deletion, MGMT promoter methylation and WHO 2021 molecular classification (all P<0.05). Patients with high KCNJ11 mRNA expression exhibited markedly longer median overall survival compared with those with low expression (P<0.05). Univariate Cox regression identified age, tumor recurrence, histopathological type, WHO grade, IDH mutation, 1p/19q co-deletion, MGMT methylation and KCNJ11 mRNA expression as OS-related risk factors (all P<0.05). Multivariate Cox regression demonstrated that age (HR = 1.015, 95%CI=1.005–1.025), tumor recurrence (HR = 2.357, 95%CI=1.833–3.031), WHO histological grade (HR = 2.256, 95%CI=1.542–3.301), IDH mutation (HR = 0.717, 95%CI=0.521–0.986), 1p/19q co-deletion (HR = 0.448, 95%CI=0.283–0.709), postoperative chemotherapy (HR = 0.588, 95%CI=0.418–0.826) and KCNJ11 mRNA expression (HR = 0.687, 95%CI=0.507–0.929) were independent prognostic determinants of OS. Consistent survival trends were observed in all three external validation cohorts (TCGA, REMBRANDT, GSE16011): high KCNJ11 expression consistently predicted prolonged median OS (all P<0.05).

Conclusion: KCNJ11 mRNA expression level in glioma tissues is inversely associated with tumor malignant progression, with lower expression detected in higher-grade, more malignant gliomas. KCNJ11 mRNA expression serves as an independent protective prognostic biomarker for glioma patients. Furthermore, elevated KCNJ11 expression predicts superior temozolomide chemosensitivity, indicating potential clinical value for individualized adjuvant chemotherapy stratification.

Related

  1. Prognostic Significance of p53 Immunohistochemical Expression and Molecular Characterization of TP53 Variants in Triple-Negative Breast Cancer After Neoadjuvant Chemotherapy
    Juan Ramón Berenguer-Marí, Luis Álvarez, Julia Sierra-Roca +8
    Diagnostics (Basel, Switzerland)Peer-reviewedCC BYFull textGeneral medicineEurope PMC
  2. Clinicopathological Significance of CD44 and CD117 Expression/Co-Expression in Invasive Ductal Breast Cancer
    Miodrag Djordjevic, Aleksandar Karanikolic, Ljubinka Velickovic
    Diagnostics (Basel, Switzerland)Peer-reviewedCC BYFull textGeneral medicineEurope PMC
  3. The Correlation of PD-L1 Expression with Tumor Budding: Evaluating the Significance of Scoring Differences in Non-Small Cell Lung Cancer
    Funda Canaz, Furkan Albayrak, Güntülü Ak +5
    BiomedicinesPeer-reviewedCC BYFull textGeneral medicineEurope PMC
  4. ¹⁵O-water PET-detected myocardial ischaemia and CT-derived FFR: Predicting the functional significance of anatomical stenosis.
    Vornanen J, Okkonen M, Ronkainen A-P +3
    Clinical physiology and functional imagingPeer-reviewedCC BY-NCFull textMedical imaging & radiologyEurope PMCPMC
  5. Expression of NECTIN-4 and TROP-2 in Resected Upper Tract Urothelial Carcinoma with and Without Preoperative Chemotherapy
    Leticia C. Clemente, Daniel A. Igel, Jesse T.R. Spooner +4
    European urology open sciencePeer-reviewedCC BY-NC-NDFull textGeneral medicineEurope PMC

Cite

BibTeXRIS
BibTeX
@article{zhou2026potassium,
  title = {{Potassium inward rectifier channel subfamily J member 11 mRNA expression in glioma and its significance in predicting prognosis and chemotherapy sensitivity}},
  author = {Kaijia Zhou and Bing Zhou and Qiang Gu and Tingming Lu and Qingxian Ke and Xiaoyin Liu and Jin Xu and Xinyan Zhang},
  journal = {Frontiers in Oncology},
  year = {2026},
  month = oct,
  doi = {10.3389/fonc.2026.1949969},
  url = {https://www.frontiersin.org/articles/10.3389/fonc.2026.1949969/full},
  note = {CC BY 4.0},
}
RIS
TY  - JOUR
TI  - Potassium inward rectifier channel subfamily J member 11 mRNA expression in glioma and its significance in predicting prognosis and chemotherapy sensitivity
AU  - Kaijia Zhou
AU  - Bing Zhou
AU  - Qiang Gu
AU  - Tingming Lu
AU  - Qingxian Ke
AU  - Xiaoyin Liu
AU  - Jin Xu
AU  - Xinyan Zhang
PY  - 2026
DA  - 2026/10/23
JO  - Frontiers in Oncology
DO  - 10.3389/fonc.2026.1949969
UR  - https://www.frontiersin.org/articles/10.3389/fonc.2026.1949969/full
AB  - Background: This study aimed to characterize the expression profile of potassium inward rectifier channel subfamily J member 11 (KCNJ11) across diverse pathological subtypes of glioma based on clinical samples from our single-center cohort. We further explored the predictive value of KCNJ11 mRNA expression for overall prognosis and temozolomide chemosensitivity in glioma patients, and validated its clinical predictive efficiency.  Methods: A total of 516 glioma patients treated at the Neuro-Oncology Surgery Department of Fujian Cancer Hospital between 2006.01and 2025.01 were enrolled as the discovery cohort. Complete clinical information including gender, age, pathological subtype, WHO histological grade, IDH mutation status, 1p/19q co-deletion status, survival outcome and KCNJ11 mRNA expression levels were retrospectively collected. Univariate and multivariate Cox proportional hazards regression models were constructed to screen independent prognostic biomarkers for glioma. Three independent public glioma datasets were applied for external validation: 603 glioma cases from The Cancer Genome Atlas (TCGA), 284 cases from the Repository for Molecular Brain Neoplasia Data (REMBRANDT), and 264 cases from GSE16011 dataset in NCBI Gene Expression Omnibus (GEO). Correlations between KCNJ11 mRNA expression, clinical molecular features and overall survival (OS) were verified across all validation cohorts.  Results: In our single-center discovery cohort of 516 glioma patients hospitalized from 2006 to 2025, KCNJ11 mRNA expression was significantly correlated with pathological subtype, WHO grade, IDH mutation, 1p/19q co-deletion, MGMT promoter methylation and WHO 2021 molecular classification (all P<0.05). Patients with high KCNJ11 mRNA expression exhibited markedly longer median overall survival compared with those with low expression (P<0.05). Univariate Cox regression identified age, tumor recurrence, histopathological type, WHO grade, IDH mutation, 1p/19q co-deletion, MGMT methylation and KCNJ11 mRNA expression as OS-related risk factors (all P<0.05). Multivariate Cox regression demonstrated that age (HR = 1.015, 95%CI=1.005–1.025), tumor recurrence (HR = 2.357, 95%CI=1.833–3.031), WHO histological grade (HR = 2.256, 95%CI=1.542–3.301), IDH mutation (HR = 0.717, 95%CI=0.521–0.986), 1p/19q co-deletion (HR = 0.448, 95%CI=0.283–0.709), postoperative chemotherapy (HR = 0.588, 95%CI=0.418–0.826) and KCNJ11 mRNA expression (HR = 0.687, 95%CI=0.507–0.929) were independent prognostic determinants of OS. Consistent survival trends were observed in all three external validation cohorts (TCGA, REMBRANDT, GSE16011): high KCNJ11 expression consistently predicted prolonged median OS (all P<0.05).  Conclusion: KCNJ11 mRNA expression level in glioma tissues is inversely associated with tumor malignant progression, with lower expression detected in higher-grade, more malignant gliomas. KCNJ11 mRNA expression serves as an independent protective prognostic biomarker for glioma patients. Furthermore, elevated KCNJ11 expression predicts superior temozolomide chemosensitivity, indicating potential clinical value for individualized adjuvant chemotherapy stratification.
SN  - 2234-943X
ER  -